Results 21 to 30 of about 43,174 (164)

Thrombotic Microangiopathies [PDF]

ISRN Hematology, 2012
Thrombotic microangiopathy results from thrombotic occlusion of the microvasculature leading to fragmentation of red blood cells, profound thrombocytopenia, and a microangiopathic hemolytic anemia with elevation of lactate dehydrogenase and negative direct Coomb’s test.
Radhi, Mohamed, Carpenter, Shannon L.
openaire   +3 more sources

The thrombotic microangiopathies [PDF]

Pediatric Nephrology, 2008
The term thrombotic microangiopathy (TMA) encompasses a group of conditions that are defined by, or result from, a similar histopathological lesion. Hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and several other conditions are associated with TMA.
Copelovitch, Lawrence, Kaplan, Bernard S.   +1 more
openaire   +2 more sources

Syndromes of Thrombotic Microangiopathy [PDF]

New England Journal of Medicine, 2014
This review article covers the diverse pathophysiological pathways that can lead to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys and other organs.
Koemhoff, Martin, Roofthooft, Marcus T., van Spronsen, Francinus   +2 more
openaire   +7 more sources

Pathogenesis of Thrombotic Microangiopathies [PDF]

Annual Review of Pathology: Mechanisms of Disease, 2007
Profound thrombocytopenia and microangiopathic hemolytic anemia characterize thrombotic microangiopathy, which includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TTP has at least three types: congenital or familial, idiopathic, and nonidiopathic.
X Long, Zheng, J Evan, Sadler
openaire   +2 more sources

Thrombotic Microangiopathy and the Kidney [PDF]

Clinical Journal of the American Society of Nephrology, 2017
Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases ...
Brocklebank V, Wood KM, Kavanagh D
openaire   +3 more sources

Viral-associated thrombotic microangiopathies [PDF]

, 2011
Thrombotic microangiopathies encompass a group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia associated with hyaline thrombi (comprised primarily of platelet aggregates in the microcirculation), and varying degrees of ...
Lopes da Silva, Rodrigo, Rodrigo Lopes da Silva   +1 more
core   +1 more source

A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies [PDF]

, 2023
The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement ...
BSH Committee, Dutt, T, Westwood, JP, Rayment, R, Clark, A, Cranfield, T, McIntyre, J, Bagot, CN, Lester, W, Scully, M, Sankar, V, Gale, D, Taylor, A, Gooding, R   +13 more
core   +1 more source

Cancer and Thrombotic Microangiopathy [PDF]

Journal of Oncology Practice, 2016
Cancer-Associated Thrombotic Microangiopathy Thrombotic microangiopathy (TMA) is a general term that describes the clinical features of thrombocytopenia and microangiopathic hemolytic anemia, in conjunction with a raised lactate dehydrogenase level, reticulocytosis, and often hyperbilirubinemia.
openaire   +2 more sources

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida, Kazushige Yazawa, Isao Tsumiyama, Hiromitsu Kayama, Sandra P. Reyna, Farid Khan, Richard S. Finkel   +8 more
wiley   +1 more source

Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV

Advanced Science, EarlyView.
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes, Gabriela Silva, Mafalda Aleixo, Marta Gomes, Daniel Simão, Stephan J. Holtkamp, Diana D. Lobo, Pradeep Harish, Rosalind Jenkins, Lekh N. Dahal, Rui J. Nobre, Luís de Pereira de Almeida, Mark Trautwein, Paula M. Alves, Catarina Brito   +14 more
wiley   +1 more source